SEC Form 4 · accession 0001916048-26-000014
Mineralys Therapeutics, Inc. · MLYS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Eric Warren
Officer — Chief Commercial Officer
Period of report
Sep 21, 2026
Accepted (ET)
Sep 22, 2026 · 6:48 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001933414
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Sep 21, 2026 | M | 7,438 | $13.24 | A | 45,838 | D | |
| Common StockF2 | Sep 21, 2026 | S | 7,438 | $28.1172 | D | 38,400 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock OptionF3 | $13.24 | Sep 21, 2026 | M | 7,438 | D | — | Apr 21, 2035 | Common Stock | 7,438 | 230,563 | D |
Explanation of responses
- F1These transactions were effected pursuant to a Rule 10b5-1 stock selling plan adopted on March 27, 2026.
- F2The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $27.94 to $28.21. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4.
- F3The stock option vested as to 25% of the underlying shares on the first anniversary of the grant date, with the remaining shares vesting in 36 substantially equal monthly installments thereafter.